PCSK9抑制剂:聚焦埃沃洛库马布及其对动脉样硬化进展的影响
1Department of Pharmacology and Toxicology, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Pharmaceuticals (Basel, Switzerland)
|January 8, 2025
概括
像Evolocumab这样的PCSK9抑制剂,通过显著降低LDL-C,在治疗动脉样硬化方面取得了突破. 这些单克隆抗体为无法通过他类药物达到胆固醇目标的患者提供了安全有效的选择.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉样性心血管疾病 (ASCVD) 是全球主要的死亡原因,与高低密度脂蛋白胆固醇 (LDL-C) 有关.
- 蛋白转化酶亚素/素9型 (PCSK9) 在调节LDL-C水平方面发挥着关键作用.
研究的目的:
- 审查PCSK9抑制剂,特别是Evolocumab在治疗动脉样硬化方面的治疗应用.
- 根据最近的临床试验数据,评估PCSK9抑制剂的疗效和安全性.
主要方法:
- 关于PCSK9抑制剂的最近研究的文献综述.
- 分析了包括FOURIER,ODYSSEY OUTCOMES和VESALIUS-CV.在内的随机对照试验的数据.
主要成果:
- 作为单克隆抗体的PCSK9抑制剂有效降低LDL-C水平约50%.
- 这些抑制剂在治疗各种心血管疾病方面已经证明了安全性和有效性.
结论:
- PCSK9抑制剂代表了ASCVD治疗的重大进展.
- 对于不耐受他类药物的患者或那些在最大的他类药物治疗中无法达到LDL-C目标的患者来说,它们至关重要.
更多相关视频
相关概念视频
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
1
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
1
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
529
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
529
01:38Inflammation
52.5K
Overview
52.5K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
465
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
465